Boundless Bio on its $100 Million IPO

anguyencooley on September 11, 2024

Cooley advised the underwriters in Boundless Bio’s $100 million initial public offering. Partners Charlie Kim, Denny Won and Charles Bair led the Cooley team. Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA).

CapitalXchange® is a registered service mark of Cooley LLP.

Disclaimer
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, Cooley SG LLP, Cooley HK or any other Cooley entity (collectively referred to as “Cooley”). By reviewing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice, and it is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep it confidential. This content may be considered Attorney Advertising and is subject to our legal notices. The views expressed on the blog do not constitute legal advice, and are the views of the authors only and not those of Cooley.

Legal notices & privacy policy

Categories

Tags

Archives

Boundless Bio on its $100 Million IPO

Related